Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

EyePoint Pharmaceuticals (EYPT) Non-Current Deffered Revenue: 2011-2017

Historic Non-Current Deffered Revenue for EyePoint Pharmaceuticals (EYPT) over the last 7 years, with Dec 2017 value amounting to $42,000.

  • EyePoint Pharmaceuticals' Non-Current Deffered Revenue fell 26.32% to $42,000 in Q4 2017 from the same period last year, while for Dec 2017 it was $42,000, marking a year-over-year decrease of 26.32%. This contributed to the annual value of $51,000 for FY2017, which is 99.09% down from last year.
  • Per EyePoint Pharmaceuticals' latest filing, its Non-Current Deffered Revenue stood at $42,000 for Q4 2017, which was down 10.64% from $47,000 recorded in Q3 2017.
  • In the past 5 years, EyePoint Pharmaceuticals' Non-Current Deffered Revenue ranged from a high of $6.1 million in Q4 2013 and a low of $42,000 during Q4 2017.
  • Moreover, its 3-year median value for Non-Current Deffered Revenue was $5.6 million (2016), whereas its average is $3.3 million.
  • Per our database at Business Quant, EyePoint Pharmaceuticals' Non-Current Deffered Revenue skyrocketed by 51.88% in 2013 and then crashed by 99.16% in 2017.
  • Quarterly analysis of 5 years shows EyePoint Pharmaceuticals' Non-Current Deffered Revenue stood at $6.1 million in 2013, then declined by 7.99% to $5.6 million in 2014, then remained steady at $5.6 million in 2015, then tumbled by 98.98% to $57,000 in 2016, then declined by 26.32% to $42,000 in 2017.
  • Its Non-Current Deffered Revenue stands at $42,000 for Q4 2017, versus $47,000 for Q3 2017 and $51,000 for Q2 2017.